Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

31.37
-2.7000-7.92%
Post-market: 31.03-0.3400-1.08%17:35 EDT
Volume:4.02M
Turnover:128.35M
Market Cap:5.97B
PE:-10.90
High:33.89
Open:33.37
Low:30.86
Close:34.07
Loading ...

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial

MT Newswires Live
·
01 Apr

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients With Variant Attr-Cm

THOMSON REUTERS
·
31 Mar

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

GlobeNewswire
·
31 Mar

BridgeBio Pharma Initiated at Buy by Redburn Atlantic

Dow Jones
·
31 Mar

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target

MT Newswires Live
·
31 Mar

Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
31 Mar

Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy

Insider Monkey
·
30 Mar

BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition

MT Newswires Live
·
27 Mar

BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM

Reuters
·
27 Mar

BridgeBio announces Japanese MHLW approved acoramidis for treating ATTR-CM

TIPRANKS
·
27 Mar

BridgeBio Pharma- Will Receive a $30 Mln Milestone Payment Upon Approval in Japan

THOMSON REUTERS
·
27 Mar

Beyonttra™ (Acoramidis), the First Near-Complete Ttr Stabilizer (≥90%), Approved in Japan to Treat Attr-Cm

THOMSON REUTERS
·
27 Mar

BridgeBio Pharma Inc - Will GET Royalties in Low Double Digits on Sales of Acoramidis in Japan

THOMSON REUTERS
·
27 Mar

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

GlobeNewswire
·
27 Mar

BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax

Reuters
·
27 Mar

BUZZ-Pfizer's heart disease drug remains 'mainstay treatment' despite new entries, Oppenheimer says

Reuters
·
26 Mar

BridgeBio Pharma Is Maintained at Overweight by JP Morgan

Dow Jones
·
24 Mar

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy

Reuters
·
24 Mar

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
22 Mar

Alnylam Stock Jumps After the FDA Approves Its Heart Drug -- WSJ

Dow Jones
·
22 Mar